Compare Capri Holdings Ltd (CPRI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

CPRI trades at $14.68, up slightly by 0.07% today, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined to $4.44 billion in 2025, and net income was negative $1.18 billion, though 2026 projections show a return to profitability. The company's balance sheet shows total assets of $5.21 billion against liabilities of $4.84 billion, with a high ROE of 252.89% but modest net income margin of 4.44%.

The outlook is mixed: analyst consensus is a Buy with a $20.57 price target, implying significant upside, but recent news highlights turnaround risks and a lowered 2027 sales view. Key risks include Michael Kors brand weakness and competitive pressures in the luxury sector. Cash flow trends show consistent negative net cash flow, adding to execution concerns amid efforts to revitalize brands.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.